Akebia Therapeuticsincis A Biopharmaceutical Company Based In Cambridgemassachusettsfocused On Developing Therapies For Rare Diseasesparticularly Kidney Disease And Metabolic Disordersfounded In 2007Akebia Aims To Improve The Lives Of Individuals Affected By Kidney Conditions By Creating Innovative Therapeutics That Set New Standards Of Care The Company Has A Strong Leadership Team And Operates As A Fully Integrated Biopharmaceutical Entity With Both Commercial And Development Capabilitiesakebia S Key Products Include Vadadustatan Fda Approved Treatment For Anemia In Chronic Kidney Diseaseand Ferric Citratewhich Addresses Hyperphosphatemia And Iron Deficiency Anemiathe Company Is Also Developing Other Investigational Treatments For Acute Kidney Injury And Retinopathy Of Prematurity Akebia Collaborates With Otsuka Pharmaceutical For The Development And Commercialization Of Vadadustat And Engages With The Renal Community To Advance Its Missionwith Operations In The U S Irelandand The U K Akebia Is Positioned Within A Dynamic Biotech Environment That Encourages Innovation And Collaboration
